Back to news

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

ACCESSWIRE•06/11/2026•16:15 ET
1

Key Highlights

  • ➤Six proposals approved at Jaguar Health’s November 6, 2026 special meeting
  • ➤Stockholders approved all submitted proposals
  • ➤Jaguar develops plant-derived prescription drugs for complicated gastrointestinal diseases

SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting of Stockholders (the "Special Meeting").

Six proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on October 8, 2026 and supplemental information filed with the SEC. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in